Prevention of oral candidiasis during radiotherapy for head and neck cancer by orabi

JRCT ID: jRCTs071190023

Registered date:03/09/2019

Basic Information

• Recruitment status: Complete
• Health condition(s) or Problem(s) studied: Head and neck cancer
• Date of first enrollment: 10/04/2020
• Target sample size: 64
• Study type: Interventional
• Intervention(s): Orabi group: Orabi is administrated when grade II oral mucositis developed.

Outcome(s)

• Primary Outcome: Development of oral candidiasis
• Secondary Outcome: Development of grade 3 oral mucositis, period until healing of oral candidiasis, investigation of factors related to development of oral candidiasis

Key inclusion & exclusion criteria

• Age minimum: >= 20age old
• Age maximum: <= 90age old
• Gender: Both
• Include criteria: Patients with head and neck cancer undergoing radiotherapy
• Exclude criteria: Patients with problem in judgement

Related Information

• Primary Sponsor: Soutome Sakiko
• Source(s) of Monetary Support: Sosei Corporation